Generic Name: talazoparib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.
Talzenna interferes with poly (ADP-ribose) polymerase, or PARP proteins, which play a role in DNA repair. Inhibiting PARP leads to more DNA breaks in cancer cells, which can halt cell division.
The EMBRACA trial showed that Talzenna slows disease progression and improves response rates compared with chemotherapy in people with advanced or metastatic breast cancer. The median duration of progression-free survival was 8.6 months in the Talzenna group versus 5.6 months in the chemotherapy group—a 46 percent lower likelihood of disease progression.
Talzenna is taken as a once-daily capsule with or without food.
Common side effects include fatigue, headache, nausea, vomiting, diarrhea, decreased appetite, hair loss and blood cell deficiencies. Talzenna can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. The Talzenna label includes a warning about myelodysplastic syndrome or acute myeloid leukemia, which occurred in a very small number of people who took the drug in clinical studies.
For More Info: https://www.talzenna.com/
Patient Assistance Program Info: https://www.pfizeroncologytogether.com/patient/talzenna/patient-financial-assistance
Last Reviewed: October 16, 2018